trending Market Intelligence /marketintelligence/en/news-insights/trending/ZvgLS0Ar3RsE1J0a5R6slg2 content esgSubNav
In This List

US FDA approves remote programming option for Cochlear's hearing implants

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA approves remote programming option for Cochlear's hearing implants

Cochlear Ltd. received approval from the U.S. Food and Drug Administration for first remote programming option for its hearing implant devices, the Nucleus Cochlear Implant System.

The regulator approved remote feature to allow follow-up programming sessions for the implant through a telemedicine platform.

Cochlear said supplemental labeling, including instructions for use, will be added in 2018 to Custom Sound, its fitting software, to guide clinicians in remote programming.